1. Home
  2. IDR vs CBIO Comparison

IDR vs CBIO Comparison

Compare IDR & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Strategic Resources Inc.

IDR

Idaho Strategic Resources Inc.

HOLD

Current Price

$28.28

Market Cap

481.0M

ML Signal

HOLD

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$14.37

Market Cap

537.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDR
CBIO
Founded
1996
2003
Country
United States
United States
Employees
62
N/A
Industry
Precious Metals
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
481.0M
537.5M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
IDR
CBIO
Price
$28.28
$14.37
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $26.67
AVG Volume (30 Days)
165.4K
★ 386.5K
Earning Date
05-13-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 70.15
N/A
EPS
★ 0.63
N/A
Revenue
★ $42,406,253.00
$18,500.00
Revenue This Year
$25.52
N/A
Revenue Next Year
N/A
$279.20
P/E Ratio
$45.65
★ N/A
Revenue Growth
★ 64.59
N/A
52 Week Low
$26.02
$8.72
52 Week High
$54.70
$27.41

Technical Indicators

Market Signals
Indicator
IDR
CBIO
Relative Strength Index (RSI) 40.76 35.19
Support Level $27.01 $9.95
Resistance Level $35.52 $18.53
Average True Range (ATR) 1.30 1.45
MACD -0.07 -0.52
Stochastic Oscillator 17.68 13.36

Price Performance

Historical Comparison
IDR
CBIO

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: